Rheumatoid arthritis and cardiovascular risk: keep it simple and compassionate

Review Rheumatology

Systematic review of associations between concomitant rheumatoid arthritis and peripheral arterial disease, health-related quality of life and functional capacity

Tayser Zoubi et al.

Summary: Patients with rheumatoid arthritis (RA) are at a higher risk for cardiovascular disease and vascular morbidity. This review investigates the relationship between RA and peripheral arterial disease (PAD) as well as the association between RA and ankle-brachial pressure index (ABPI). It also examines the impact of concurrent diseases on health-related quality of life (HRQOL) and functional capacity (FC).

RHEUMATOLOGY INTERNATIONAL (2023)

添加到收藏夹

Article Rheumatology

Effect of anti-inflammatory therapy on vascular biomarkers for subclinical cardiovascular disease in rheumatoid arthritis patients

Annelies B. Blanken et al.

Summary: This study assessed the effect of 4 years of anti-inflammatory therapy on markers of subclinical vascular disease in rheumatoid arthritis patients. The results showed modest beneficial changes in some surrogate markers of subclinical vascular disease after anti-inflammatory therapy, which were associated with improvement in disease activity markers.

RHEUMATOLOGY INTERNATIONAL (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

Steven Hageman et al.

Summary: The study aimed to develop, validate, and demonstrate an updated prediction model (SCORE2) to estimate 10-year cardiovascular disease risk in individuals without previous history of CVD or diabetes in Europe. The new algorithm, SCORE2, enhances the identification of individuals at higher risk of developing CVD across Europe by predicting first-onset CVD risk in European populations.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

James P. Howard et al.

Summary: The study found that the majority of symptoms caused by statin tablets were actually due to the placebo effect, suggesting that clinicians should be cautious when attributing symptoms to the medication. The research also indicated that there was no significant difference between abandoning statins and placebos, and the relief of symptoms after stopping medication was similar in both groups.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal